A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian

Coleman, Robert

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian

Saturday, March 28, 2015: 8:17 AM

International Ballroom (Hilton Chicago)

R. L. Coleman¹, M. F. Brady², T. J. Herzog³, P. Sabbatini⁴, D. K. Armstrong⁵, J. L. Walker⁶, B. G. Kim⁷, K. Fujiwara⁸, K. S. Tewari⁹, D. M. O'Malley¹⁰ and S. A. Davidson¹¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²University of Buffalo, Buffalo, NY, ³University of Cincinnati, Cincinnati, OH, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, ⁵Johns Hopkins Kimmel Cancer Center, Baltimore, MD, ⁶The University of Oklahoma, Oklahoma City, OK, ⁷Sungkyunkway University School of Medicine, Seoul, South Korea, ⁸Saitama Medical University International Medical Center, Hidaka-Shi, Japan, ⁹UC Irvine Medical Center, Orange, CA, ¹⁰The Ohio State University, James Cancer Hospital, Columbus, OH, ¹¹University of Colorado Denver, Aurora, CO

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian